# First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

Source: https://onco.cc/trials/nct06840782/  
OnCo record `nct06840782` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Gustave Roussy, Cancer Campus, Grand Paris, now recruiting.

## Summary

First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients. is a phase 3, randomised interventional study registered as NCT06840782 by Gustave Roussy, Cancer Campus, Grand Paris, with a registry enrolment figure of 124 participants, started 2025-09-09 and due to reach its primary completion in 2030-02. Interventions recorded: Radical local treatment; SoC-based immunotherapy (+/- chemotherapy). Conditions listed: Oligometastatic Non-small Cell Lung Cancer (NSCLC). Primary outcome: Overall Survival (OS).. Lung eligibility wording from the registry: "* Histologically proven advanced synchronous oligometastatic stage IV NSCLC". Sites: France. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: OliGRAIL
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06840782
- Phase: 3
- Setting: First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients: a Randomized, Multicentre, Open-label Phase III Study
- Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Enrolled: 124

## Sources

- ClinicalTrials.gov NCT06840782: https://clinicaltrials.gov/study/NCT06840782

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06840782.json